Best Genomics Companies in North Carolina, United States
The 71 best Genomics companies in North Carolina, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AskBio.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in North Carolina
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AskBio Developer of AAV technologies for treating genetic and complex disorders | $235M | 69 mo ago | 900 | Jude Samulski Co-Founder & CSO | WordPress Block EditorElementorWordPress+25 | Top 5M | 75 patents AAV-based gene therapy vectors for kidney delivery and neurological disease treatment | 1 partnership · 1 award |
| 2 | GenetronHealth Provider of services in the development of precision medicine tools for cancer treatment | $191M | 79 mo ago | 993 | Sizhen Wang Co-Founder & CEO | BootstrapNginxSwiper+6 | Top 10M | — | 1 launch |
| 3 | Metabolon Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine | $173M | 16 mo ago | 189 189 → 203 (+7%) | — | WordPressApple iCloud MailMicrosoft 365+39 | Top 5M | 400 patents Metabolomics-based biomarker discovery and diagnostic assays for metabolic and inflammatory diseases. | — |
| 4 | Pairwise Provider of gene editing technology for climate-resilient, nutritious, and sustainable crops | $155M | 21 mo ago | 163 | Tom Adams CEO | WebflowGSAPLeadfeeder+19 | Top 10M | — | 1 internship · 1 partnership · 1 award |
| 5 | Precision BioSciences Developer of gene editing therapies to treat rare genetic diseases 57Product top 19%Funding top 21%Moat top 32%Patents top 36% All 11 signals ▾Producttop 19% Fundingtop 21% Moattop 32% Patentstop 36% Newstop 38% Markettop 39% Techtop 41% Innovationtop 42% Growthbottom 47% Globalbottom 42% Fin. healthbottom 39% Product: 3 distinct product lines · Company stage: Public Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $136M | 3 mo ago | 236 | — | DrupalApple iCloud MailMicrosoft 365+23 | Top 10M | 68 patents Precise gene editing tools for therapeutic targets and engineered cell therapies | — |
| 6 | StrideBio Developer of AAV based gene therapies for rare diseases | $98M | 63 mo ago | 109 | — | — | — | 89 patents Recombinant adeno-associated virus vector production and gene‑therapy delivery systems. | — |
| 7 | Xilis Developer of drug discovery and precision therapy platform for oncology 53Patents top 21%Moat top 21%Innovation top 22%Funding top 26% All 9 signals ▾Patentstop 21% Moattop 21% Innovationtop 22% Fundingtop 26% Talentbottom 49% Marketbottom 46% Globalbottom 42% Techbottom 29% Newsbottom 22% Patents: 97 patents matched (strict assignee match) · 96 filings since 2022 vs 1 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $89M | 14 mo ago | 72 | Hans Clevers Co-Founder | WordPressMySQLPHP+16 | Top 50M | 97 patents Microfluidic organoid droplet generation and component delivery for personalized medicine | — |
| 8 | Locus Biosciences Developer of therapeutics for infectious disease and inflammatory indications | $67M | 29 mo ago | 74 74 → 61 (-18%) | Paul Garofolo Chief Executive Officer | WordPress Block EditorWordPressMySQL+24 | Top 10M | 60 patents Engineered CRISPR‑enhanced bacteriophage therapeutics targeting antibiotic‑resistant bacterial infections | — |
| 9 | Ribometrix Provider RNA-targeted drug discovery platform | $65M | 80 mo ago | 26 | — | — | — | 9 patents eIF4E inhibitor small molecules for oncology therapeutics | — |
| 10 | Bamboo Therapeutics Developer of gene therapies to treat rare central nervous system and neuromuscular diseases | $49M | 124 mo ago | 27 | — | — | — | — | — |
| 11 | Athenix Provider of agricultural biotechnology solutions | $44M | 215 mo ago | 60 | — | — | — | 853 patents Genetically engineered insecticidal proteins for agricultural pest control | — |
| 12 | Codetta Online platform for analyzing omics clinical data | $27M | 25 mo ago | 21 | — | — | — | — | — |
| 13 | GeneCentric Developer of diagnostics for cancer classification and treatment | $19M | 12 mo ago | 19 | — | WordPressMySQLPHP+21 | Top 50M | — | — |
| 14 | Biofluidica Provider of liquid biopsy tests using CTCs | $18M | 51 mo ago | 13 13 → 7 (-46%) | Steven Soper Co-Founder & CTO | — | — | 20 patents Microfluidic platforms for high‑efficiency isolation of rare biomarker and fetal cells | — |
| 15 | Saga Diagnostics Provider of tests for detection and analysis of circulating tumor DNA | $18M | 59 mo ago | 23 | Lao Saal Founder | WordPressApple iCloud MailMicrosoft 365+26 | Top 5M | — | — |
| 16 | Bioskryb Developer of a genome sequencing and amplification system | $12M | 77 mo ago | 21 21 → 40 (+90%) | Jay West Co-Founder & CEO | — | — | 8 patents High‑sensitivity nucleic‑acid amplification and single‑cell genomic analysis technologies | 1 launch |
| 17 | Tavros Developer of small-molecule therapeutics for cancer | $10M | 44 mo ago | 13 | Kris Wood Co-Founder | — | — | — | — |
| 18 | Hi Fidelity Genetics Developer of a predictive breeding platform to identify crop traits and build crop models | $8M | 90 mo ago | 24 | Spencer Maughan Co-Founder & Chairman | WordPressMySQLPHP+10 | Top 50M | 37 patents Non‑invasive root phenotyping for agricultural plant imaging and phenomics | — |
| 19 | NanoCor Therapeutics Developer of targeted drug delivery system for the treatment of CHF | $8M | 225 mo ago | — | Sheila Mikhail CEO | — | — | — | — |
| 20 | Gentris A provider of pharmacogenomic testing and biorepository services | $6M | 253 mo ago | 40 | — | — | — | 2 patents Generating reference controls for pharmacogenomic testing | — |
| 21 | Celldom Developer of single cell analysis device | $6M | 14 mo ago | 9 | Zachary Forbes Founder & CEO | — | — | 8 patents Microfluidic single-cell assay platforms for drug screening and barcoded particle analysis | — |
| 22 | Triangle Biotechnology Provider of reagents for genomic and epigenetic assays | $6M | 34 mo ago | 11 | — | — | — | 18 patents Microfluidic sample preparation, nanodroplet-mediated microbial lysis, and biofilm disruption using nanoparticles. | — |
| 23 | Gusto Global Developer of microbiome technology to detect infectious diseases | $6M | 45 mo ago | 4 | — | — | — | 30 patents Microbial diagnostics and therapeutics via targeted amplicon sequencing and EV RNA analysis | — |
| 24 | OncoTrap Developer of in vivo nucleic delivery technology and de novo protein engineering technology | $5M | 33 mo ago | 5 | — | — | — | — | — |
| 25 | Element Genomics Developer of epigenomic editing platform | $5M | 115 mo ago | 12 | John Oxaal Co-Founder | — | — | — | — |
| 26 | Atom Bioworks Developer of DNA nanostructures for various applications | $3M | 14 mo ago | 8 | Sherwood Yao CEO | WordPressMySQLPHP+18 | Top 50M | 6 patents Nucleic‑acid nanostructure platforms for cancer and viral disease detection and therapy | 1 launch |
| 27 | Galaxy Diagnostics PCR-based Human and Animal testing for vector-borne diseases | $3M | 14 mo ago | 15 | — | Cart FunctionalityWordPressMySQL+33 | Top 5M | — | — |
| 28 | Vindara Online retailer of domain names with options for payment plans | $2M | 64 mo ago | 6 | Jade Stinson Co-Founder & CSO | — | — | 4 patents Lettuce breeding methods and seed/composition technologies for new Lactuca sativa varieties. | — |
| 29 | Enzerna Developer of novel molecular tools to modulate gene expression in any organism | $1M | 46 mo ago | 9 | — | — | — | — | — |
| 30 | Genoverde Provider of genetically engineering plants for higher carbon sequestration | $1M | 93 mo ago | — | Samuel Hazen Co-Founder & CSO | — | — | — | — |
| 31 | SNP Therapeutics Provider of gene-guided precision nutrition for various health conditions | $1M | 82 mo ago | 7 | Steven Zeisel Founder | — | — | — | — |
| 32 | Entogenetics Provider of genetically engineered spider silk from silkworms for commercial-scale production | $540K | 155 mo ago | 11 | David Brigham Founder & CEO | — | — | 9 patents Biotechnological production of recombinant spider silk proteins for advanced biomaterials | — |
| 33 | Neuronano Pharma Developer of formulation and drug delivery technologies | $440K | 102 mo ago | — | Zagit Gaymalov Co-Founder & CEO | — | — | — | — |
| 34 | Data Driven Bioscience Machine learning-enabled cancer genomics diagnostic kits | $301K | 17 mo ago | 4 | Sandeep Dave Founder | — | — | — | — |
| 35 | Avalo Developer of a platform for accelerated crop breeding and evolution | $250K | 15 mo ago | 10 | Brendan Collins Co-Founder | — | — | 14 patents AI-driven bioinformatics platforms for genomic, gene‑environment and spectral data analysis | 1 partnership |
| 36 | Kalia Health Developer of a home-based prenatal diagnostic test | $250K | 47 mo ago | 7 | — | — | — | — | — |
Top 12 Genomics companies in North Carolina
#1
Public · Durham, North Carolina · founded 2006 · 236 employees$135.7Mraised▾
Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.
- Mar 2026Post IPO$7.5M
- Jun 2022Post IPO$75M
- Mar 2019Conventional Debt$39.5M
- Jun 2018Series B$110M
#2
Series H · Morrisville, North Carolina · founded 2000 · 189 employees$173.4Mraised▾
Provider of solutions for biomarker discovery, diagnostic tests, and personalized medicine. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. It also offers Quantose IR, a lab test for prediabetes assessment and treatment, and Meta IMD, a CLIA assay for inborn errors of metabolism. The company is also developing metabolomics-based clinical diagnostic tests that may improve the early detection of obesity-related metabolic diseases.
- Feb 2025Grant (prize money)$297.7K
- Dec 2024Series H$7.5M
- May 2024Grant (prize money)$298.3K
- Sep 2023Grant (prize money)$297.7K
#3
Series B · Durham, North Carolina · founded 2019 · 72 employees$89Mraised▾
Developer of drug discovery and precision therapy platform for oncology. The company has micro-organ sphere technologies which enable rapid diagnostics, personalized drug screening, and scalable patient-derived models for immuno-oncology drug discovery.
- Apr 2025Series B$19.4M
- Apr 2025Conventional Debt—
- Feb 2025Grant (prize money)$2.4M
- Jul 2022Series A$19M
#4
Series C · Durham, North Carolina · founded 2011 · 19 employees$18.9Mraised▾
Developer of diagnostics for cancer classification and treatment. The core technology, Cancer Subtype Platform (CSP) identifies biologic subtypes through an integrated analysis of tumor genomics. The lead product, the first-generation Lung Subtyping Predictor (LSPTM) classifies tumors into squamous, adenocarcinoma, and neuroendocrine (small cell and carcinoid) lung cancer.
- Jun 2025Series C$8M
- Sep 2022Conventional Debt$2.5M
- Oct 2021Series B$7.5M
- Jan 2021Conventional Debt$1.2M
#5
Series C · Durham, North Carolina · founded 2017 · 163 employees$155Mraised▾
Provider of gene editing technology for climate-resilient, nutritious, and sustainable crops. It applies CRISPR technology to make plants easier to grow and eat. The Fulcrum platform integrates gene editing, AI, and plant biology to accelerate crop development. It develops climate-ready, disease-tolerant, and high-yield crops. The innovations include extended flowering time, compact plant size, seedless convenience, and better taste.
- Sep 2024Series C$40M
- Feb 2021Series B$90M
- Mar 2018Series A$25M
#6
Seed · Durham, North Carolina · founded 2016 · 9 employees$6.5Mraised▾
Developer of single cell analysis device. The company offers CloneXplorer is the next-generation live single-cell assay platform that combines functional imaging and molecular readouts with integrated cell retrieval to identify and characterize rare cells that play critical roles in biological pathways and disease.
- Apr 2025Grant (prize money)$1.8M
- May 2024Grant (prize money)$938.6K
- Apr 2019Seed—
- Jan 2019Grant (prize money)$2M
#7
Series A · Durham, North Carolina · founded 2009 · 15 employees$2.6Mraised▾
Galaxy Diagnostics is an infectious disease testing company founded by researchers at NC State University College of Veterinary Medicine. The company offers PCR tests to confirm Bartonella infection and other pathogens. Its product, the Bartonella ePCR test combines proprietary enrichment culture with compassionate PCR methods to provide a highly sensitive detection test for Bartonella spp. The company offers PCR tests to detect a broad range of species within each genus of Bartonella spp, Anaplasma spp, Ehrlichia spp, Rickettsia spp, and Babesia.
- Apr 2025Series A$4.1M
- Aug 2023Series A$2M
- Sep 2018Grant (prize money)$224.9K
- Aug 2014Seed$550.8K
#8
Series B · Raleigh, North Carolina · founded 2015 · 74 employees$67.3Mraised▾
Developer of therapeutics for infectious disease and inflammatory indications. The company has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria and enables the development of antimicrobials for infectious diseases.
- Jan 2024Grant (prize money)$23.9M
- May 2022Series B$35M
- Oct 2021Conventional Debt—
- Nov 2020Conventional Debt$20M
#9
Funding Raised · Cary, North Carolina · founded 2019 · 8 employees$3Mraised▾
Developer of DNA nanostructures for various applications. The company has developed a platform for programming DNA and RNA-based biomolecules as high-affinity binding reagent for various applications, including drug delivery and diagnostics for infectious diseases and cancer. It also, offers AI enabled DNA design software system provides flexibility to design and manufacture nanometre-scale biomaterial.
- Mar 2025Grant (prize money)$998.5K
- Sep 2022Grant (prize money)$1.7M
- Jun 2020Grant (prize money)$248.4K
#10
Series A · Morrisville, North Carolina · founded 2021 · 21 employees$27.3Mraised▾
Online platform for analyzing omics clinical data. The platform offers analysis of reagents, hardware, and software enabling simultaneous, multiplexed, and multi-omic analyses of liquid biopsy and isolated DNA, RNA, and protein.
- May 2024Series A$12.3M
- Apr 2022Series A$15M
#11
Acquired · Durham, North Carolina · founded 2001 · 900 employees$235Mraised▾
Developer of AAV technologies for treating genetic and complex disorders. The company is engaged in the development and delivery of novel protein and cellular-based therapies through the design of proprietary recombinant Adeno associated virus (AAV) Biological Nano Particles (BNP). The gene delivery technology platform provides unsurpassed transduction efficiency, "ramp-up" expression capabilities, with tissue targeting and de-targeting properties. Its product pipeline includes drugs to treat muscular dystrophy, hemophilia B, congestive heart failure, epilepsy, retinitis pigmentosa, and osteoporosis.
- Sep 2020Grant (prize money)$2.7M
- Apr 2019PE$235M
- Aug 2014Grant (prize money)$270K
- Sep 2010Grant (prize money)$321K
#12
Seed · Durham, North Carolina · founded 2016 · 15 employees$90Kraised▾
ScitoVation engages in offering chemical compound safety tools for the healthcare, cosmetic, and food industry. The company provides services in the mode of action of a chemical, extrapolation of the animal to human exposure, and the use of gene expression and sequencing data to ascertain toxicity. The company develops and applies technology to model scenarios and environments unique to chemical toxicity and gene expression data. These include PLETHEM (Population Lifecourse Exposure-To-Health-Effects Model Suite) a modular design platform that supports a variety of exposure and PBPK models and MoAviz which is a browser-based applet for summarizing, exploring and interpreting gene expression and other high-throughput data. The product developed by the company for transcriptomics analysis is ScitoXpress.
- Sep 2025Grant (prize money)$973.3K
- May 2025Grant (prize money)$973.3K
- Jul 2023Grant (prize money)$270K
- May 2023Grant (prize money)$1.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in the United States
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,110 United States-affiliated papers.
- Harvard University633
- Broad Institute433
- Howard Hughes Medical Institute318
- Stanford University287
- Johns Hopkins University287
- Gene83→532
- Transcriptome25→436
- Genome117→419
- Disease6→218
- Immune system11→219
- Disease17→407
- Immune system4→266
- Gene38→281
- Transcriptome13→238
- Biomarker2→208
- Disease27→311
- Immune system6→152
- Cancer17→130
- Clinical trial4→111
- Biomarker2→92
Where bioinformatics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in the United States
United States bioinformatics patent filing is accelerating — 246 filings from 64 assignees (2016–2025), led by Edico Genome, Illumina, UNIV Washington; annual filings 22→23.
- Edico Genome129
- Illumina60
- UNIV Washington18
- Nantomics9
- Genomsys7
- Baluch Mohamed Khoso7
- Microsoft6
- Contamination Source Identificat5
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.